November 6, 2017 / 9:23 PM / 8 months ago

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

Nov 6 (Reuters) - Dermira Inc

* Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​

* Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​

* Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​

* Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below